These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 11755578)

  • 1. Spontaneous reports of pulmonary embolism in association with raloxifene.
    Brinker A; Beitz J
    Obstet Gynecol; 2001 Dec; 98(6):1151. PubMed ID: 11755578
    [No Abstract]   [Full Text] [Related]  

  • 2. Raloxifene therapy.
    Heath H; Cox DA; Plouffe L
    J Am Geriatr Soc; 2000 Sep; 48(9):1170-2. PubMed ID: 10983924
    [No Abstract]   [Full Text] [Related]  

  • 3. Safety profile of raloxifene as used in general practice in England: results of a prescription-event monitoring study.
    Layton D; Clarke A; Wilton LV; Shakir SA
    Osteoporos Int; 2005 May; 16(5):490-500. PubMed ID: 15309382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Raloxifene: risks and benefits.
    Barrett-Connor E
    Ann N Y Acad Sci; 2001 Dec; 949():295-303. PubMed ID: 11795366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Benefit-risk assessment of raloxifene in postmenopausal osteoporosis.
    Cranney A; Adachi JD
    Drug Saf; 2005; 28(8):721-30. PubMed ID: 16048357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective estrogen receptor modulator raloxifene-associated aggravation of nonalcoholic steatohepatitis.
    Takamura T; Shimizu A; Komura T; Ando H; Zen Y; Minato H; Matsushita E; Kaneko S
    Intern Med; 2007; 46(9):579-81. PubMed ID: 17473493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [What can we expect of raloxifene in the treatment of postmenopausal osteoporosis--views of a gynecologist].
    Chmel R; Rob L; Strnad P
    Ceska Gynekol; 2002 Jul; 67(4):187-91. PubMed ID: 12373918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of raloxifene on bone mineral density and biochemical markers of bone turnover in Japanese postmenopausal women with osteoporosis: results from a randomized placebo-controlled trial.
    Morii H; Ohashi Y; Taketani Y; Fukunaga M; Nakamura T; Itabashi A; Sarkar S; Harper K
    Osteoporos Int; 2003 Oct; 14(10):793-800. PubMed ID: 12955333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effects of SERMs on bone health. Raloxifene effects on breast cancer and cardiovascular events].
    Inoue D
    Clin Calcium; 2010 Mar; 20(3):331-8. PubMed ID: 20190362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Raloxifene hydrochloride.
    Snyder KR; Sparano N; Malinowski JM
    Am J Health Syst Pharm; 2000 Sep; 57(18):1669-75; quiz 1676-8. PubMed ID: 11006795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tolerability profile of SERMs.
    Agnusdei D; Iori N
    J Endocrinol Invest; 1999 Sep; 22(8):641-5. PubMed ID: 10532252
    [No Abstract]   [Full Text] [Related]  

  • 12. Raloxifene: a review of its use in postmenopausal osteoporosis.
    Clemett D; Spencer CM
    Drugs; 2000 Aug; 60(2):379-411. PubMed ID: 10983739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carotid artery intima-media thickness after raloxifene treatment.
    Mack WJ; Dhungana B; Dowsett SA; Keech CA; Feng M; Li Y; Hodis HN
    J Womens Health (Larchmt); 2007 Apr; 16(3):370-8. PubMed ID: 17439382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of raloxifene therapy on venous thromboembolism in postmenopausal women. A meta-analysis.
    Adomaityte J; Farooq M; Qayyum R
    Thromb Haemost; 2008 Feb; 99(2):338-42. PubMed ID: 18278183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endometrial lesions causing uterine bleeding in postmenopausal women receiving raloxifene.
    Tsalikis T; Zepiridis L; Zafrakas M; Dinas K; Bontis J
    Maturitas; 2005 Jun; 51(2):215-8. PubMed ID: 15917163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Raloxifene and risk of vertebral fracture in postmenopausal women.
    Halbekath J; Becker-Brüser W; Wille H
    JAMA; 2000 May; 283(17):2236-7. PubMed ID: 10807376
    [No Abstract]   [Full Text] [Related]  

  • 17. Year-by-year analysis of cardiovascular events in the Multiple Outcomes of Raloxifene Evaluation (MORE) trial.
    Keech CA; Sashegyi A; Barrett-Connor E
    Curr Med Res Opin; 2005 Jan; 21(1):135-40. PubMed ID: 15881485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of postmenopausal osteoporosis with raloxifene].
    Fedelesova V; Chylova K; Dzurik
    Bratisl Lek Listy; 2000; 101(9):527-8. PubMed ID: 11187059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of selective estrogen receptor modulators (SERMs) in postmenopausal health.
    Draper MW
    Ann N Y Acad Sci; 2003 Nov; 997():373-7. PubMed ID: 14644844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Raloxifene - an unexploited possibility of prevention and treatment of postmenopausal osteoporosis].
    Štěpán J; Rosa J; Pavelka K
    Vnitr Lek; 2016; 62(10):781-788. PubMed ID: 27900864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.